664 related articles for article (PubMed ID: 28625638)
21. Effect of PD-1 inhibitor on exhaled nitric oxide and pulmonary function in non-small cell lung cancer patients with and without COPD.
Suzuki Y; Inui N; Karayama M; Imokawa S; Yamada T; Yokomura K; Asada K; Kusagaya H; Kaida Y; Matsuda H; Koshimizu N; Toyoshima M; Masuda M; Hayakawa H; Hozumi H; Furuhashi K; Enomoto N; Fujisawa T; Nakamura Y; Suda T
Int J Chron Obstruct Pulmon Dis; 2019; 14():1867-1877. PubMed ID: 31686799
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057.
Reck M; Brahmer J; Bennett B; Taylor F; Penrod JR; DeRosa M; Dastani H; Spigel DR; Gralla RJ
Eur J Cancer; 2018 Oct; 102():23-30. PubMed ID: 30103096
[TBL] [Abstract][Full Text] [Related]
23. Immune-related intestinal pseudo-obstruction associated with nivolumab treatment in a lung cancer patient.
Fragulidis G; Pantiora E; Michalaki V; Kontis E; Primetis E; Vezakis A; Polydorou A
J Oncol Pharm Pract; 2019 Mar; 25(2):487-491. PubMed ID: 29067858
[TBL] [Abstract][Full Text] [Related]
24. Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases.
Dudnik E; Yust-Katz S; Nechushtan H; Goldstein DA; Zer A; Flex D; Siegal T; Peled N
Lung Cancer; 2016 Aug; 98():114-117. PubMed ID: 27393516
[TBL] [Abstract][Full Text] [Related]
25. Nivolumab Exposure-Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Non-Small Cell Lung Cancer.
Feng Y; Wang X; Bajaj G; Agrawal S; Bello A; Lestini B; Finckenstein FG; Park JS; Roy A
Clin Cancer Res; 2017 Sep; 23(18):5394-5405. PubMed ID: 28916617
[No Abstract] [Full Text] [Related]
26. [Psoriasis and Psoriatic Arthritis Induced by Nivolumab in a Patient with Advanced Non-Small-Cell Lung Cancer].
Sugiura Y; Fujimoto H; Yamamoto M; Nomura H; Hashizume T; Kawai O; Araki N; Kawakami K; Sueki H; Fusegawa H; Ohkubo Y; Nemoto E
Gan To Kagaku Ryoho; 2017 Sep; 44(9):787-789. PubMed ID: 28912410
[TBL] [Abstract][Full Text] [Related]
27. Long-lasting shrinkage in tumor mass after discontinuation of nivolumab treatment.
Kimura H; Sone T; Murata A; Koba H; Tambo Y; Hara J; Abo M; Kasahara K
Lung Cancer; 2017 Jun; 108():7-8. PubMed ID: 28625651
[TBL] [Abstract][Full Text] [Related]
28. [Effectiveness of a Low-dose Corticosteroid in a Patient with Polymyalgia Rheumatica Associated with Nivolumab Treatment].
Imai Y; Tanaka M; Fujii R; Uchitani K; Okazaki K
Yakugaku Zasshi; 2019; 139(3):491-495. PubMed ID: 30828027
[TBL] [Abstract][Full Text] [Related]
29. Immune-related pancreatitis secondary to nivolumab in a patient with recurrent lung adenocarcinoma: A case report.
Ikeuchi K; Okuma Y; Tabata T
Lung Cancer; 2016 Sep; 99():148-50. PubMed ID: 27565931
[TBL] [Abstract][Full Text] [Related]
30. Best practice in the treatment of advanced squamous cell lung cancer.
Ang YL; Tan HL; Soo RA
Ther Adv Respir Dis; 2015 Oct; 9(5):224-35. PubMed ID: 25902866
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316).
Tachihara M; Negoro S; Inoue T; Tamiya M; Akazawa Y; Uenami T; Urata Y; Hattori Y; Hata A; Katakami N; Yokota S
BMC Cancer; 2018 Oct; 18(1):946. PubMed ID: 30285770
[TBL] [Abstract][Full Text] [Related]
32. Treatment and relapse of interstitial lung disease in nivolumab-treated patients with non-small cell lung cancer.
Sata M; Sasaki S; Oikado K; Saito Y; Tominaga J; Sakai F; Kato T; Iwasawa T; Kenmotsu H; Kusumoto M; Baba T; Endo M; Fujiwara Y; Sugiura H; Yanagawa N; Ito Y; Sakamoto T; Ohe Y; Kuwano K
Cancer Sci; 2021 Apr; 112(4):1506-1513. PubMed ID: 33125784
[TBL] [Abstract][Full Text] [Related]
33. Recurrent Episodes of Nivolumab-Induced Pneumonitis after Nivolumab Discontinuation and the Time Course of Carcinoembryonic Antigen Levels: A Case of a 58-Year-Old Woman with Non-Small Cell Lung Cancer.
de Jong C; Peters BJM; Schramel FMNH
Chemotherapy; 2018; 63(5):272-277. PubMed ID: 30572331
[TBL] [Abstract][Full Text] [Related]
34. Antitumor activity of nivolumab on hemodialysis after renal allograft rejection.
Ong M; Ibrahim AM; Bourassa-Blanchette S; Canil C; Fairhead T; Knoll G
J Immunother Cancer; 2016; 4():64. PubMed ID: 27777773
[TBL] [Abstract][Full Text] [Related]
35. Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer.
Nishino M; Chambers ES; Chong CR; Ramaiya NH; Gray SW; Marcoux JP; Hatabu H; Jänne PA; Hodi FS; Awad MM
Cancer Immunol Res; 2016 Apr; 4(4):289-93. PubMed ID: 26865455
[TBL] [Abstract][Full Text] [Related]
36. Nivolumab-induced organizing pneumonitis in a patient with lung sarcomatoid carcinoma.
Gounant V; Brosseau S; Naltet C; Opsomer MA; Antoine M; Danel C; Khalil A; Cadranel J; Zalcman G
Lung Cancer; 2016 Sep; 99():162-5. PubMed ID: 27565934
[TBL] [Abstract][Full Text] [Related]
37. Psoriasis and psoriatic arthritis induced by nivolumab in a patient with advanced lung cancer.
Law-Ping-Man S; Martin A; Briens E; Tisseau L; Safa G
Rheumatology (Oxford); 2016 Nov; 55(11):2087-2089. PubMed ID: 27436004
[No Abstract] [Full Text] [Related]
38. A case of de novo palmoplantar psoriasis with psoriatic arthritis and autoimmune hypothyroidism after receiving nivolumab therapy.
Elosua-González M; Pampín-Franco A; Mazzucchelli-Esteban R; Mielgo-Rubio X; Rodriguez-Vásquez X; García-Zamora E; López-Estebaranz JL
Dermatol Online J; 2017 Aug; 23(8):. PubMed ID: 29469753
[TBL] [Abstract][Full Text] [Related]
39. Nivolumab for second-line treatment of metastatic squamous non-small-cell lung cancer.
Rounds A; Kolesar J
Am J Health Syst Pharm; 2015 Nov; 72(21):1851-5. PubMed ID: 26490818
[TBL] [Abstract][Full Text] [Related]
40. Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme.
Grossi F; Crinò L; Logroscino A; Canova S; Delmonte A; Melotti B; Proto C; Gelibter A; Cappuzzo F; Turci D; Gamucci T; Antonelli P; Marchetti P; Santoro A; Giusti S; Di Costanzo F; Giustini L; Del Conte A; Livi L; Giannarelli D; de Marinis F
Eur J Cancer; 2018 Sep; 100():126-134. PubMed ID: 30014881
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
